Movement Disorders

Papers
(The H4-Index of Movement Disorders is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
369
May Infographic251
Movement Disorders: Volume 40, Number 6, June 2025179
Movement Disorders: Volume 40, Number 2, February 2025121
John Michael Walshe (April 24, 1920–October 14, 2022)120
Issue Information119
In Memoriam Mahlon R. DeLong (1938–2024)116
Stability of Mosaic Divergent Repeat Interruptions in X‐Linked Dystonia‐Parkinsonism114
Bidirectional Transcription at the PPP2R2B Gene Locus in Spinocerebellar Ataxia Type 12104
Fixel‐Based Analysis Reveals Whole‐Brain White Matter Abnormalities in Cervical Dystonia97
The FDA Has Ended Required Blood Monitoring for Clozapine Use—Will This Impact the Management of Parkinson's Disease Psychosis?86
Assessing Intronic Variable Number Tandem Repeat ( VNTR) Expansions of the HSF1 82
Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy80
Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy77
Treatment for Dyskinesia in Parkinson's Disease: A Network Meta‐analysis of Randomized Controlled Trials76
The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease72
Multimodal Imaging Investigation of the Dentato‐Thalamo‐Cortical Pathway in Friedreich's Ataxia72
The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?70
Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease70
The Pattern and Stages of Atrophy in Spinocerebellar Ataxia Type 2: Volumetrics from ENIGMA‐Ataxia67
Investigation of Shared Genetic Risk Factors Between Parkinson's Disease and Cancers66
Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in H65
Biallelic Variants in SLC27A3 Cause a Complex Form of Neurodegeneration with Brain Iron Accumulati63
Indirect Striatal Projection Neurons Drive a D2 Receptor‐Dependent Pathway to Dyskinesia and Dystonia62
Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease62
A GJA1 Variant Triggers Earlier SPG4 Onset by Destabilizing Deubiquitinase 60
A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease59
Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals58
Risk Factors for the Diagnosis of Progressive Supranuclear Palsy in the UK Biobank57
The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure55
Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation55
Reply to: “Early Indian Age at Onset of Parkinson's: A Case for a Gene‐Environment Lens”54
Annonaceae Consumption Worsens Disease Severity and Cognitive Deficits in Degenerative Parkinsonism54
Author Index51
Functional Movement Disorders and Drug‐Induced Movement Disorders51
Reply to: “Adult‐Onset Neurodegeneration in Nucleotide Excision Repair Disorders: More Common than Expected”50
Stress in Musicians with and Without Focal Dystonia Is Not Reflected in Limbic Circuit Activation50
Issue Information50
A CGG Repeat Expansion in CSNK1E Associated wit50
Thank you to Reviewers 202249
Obituary for Jan O. Aasly (1950–2022)48
Movement Disorders: Volume 37, Number 9, September 202248
48
Issue Information48
Derivation and Validation of a Phenoconversion‐Related Pattern in Idiopathic Rapid Eye Movement Behavior Disorder47
Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort45
Author Response to Comment on “Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations”45
0.16067004203796